Clinical Trials Logo

Filter by:
NCT ID: NCT01383889 Completed - Blood Pressure Clinical Trials

Acute Maternal and Fetal Effects of Exercise in Pregnancy

EXPREG
Start date: December 2011
Phase: N/A
Study type: Interventional

This will be an open randomized clinical trial involving pregnant women between 35 and 37 weeks randomized to two modalities of exercise: treadmill or stationary bike. The study hypothesis is that exercise on a stationary cycle causes less maternal and fetal effects in relation to treadmill exercise.We will study the acute effects of exercise for both the mother and the fetus, monitoring the parameters before, during and after exercise for 20 minutes. The exercise intensity will be moderate, remaining between 60% and 80% of maximum heart rate. Women will be monitored with a recording equipment of ABPM (ambulatory blood pressure monitorization) and continuous cardiotocography and blood will be collected to measure blood glucose, total cholesterol and HDL, nitrate and lactate before, during and after exercise. The analysis variables are: maternal heart rate and blood pressure, fetal heart rate, number of fetal movements, transient accelerations, decelerations, short-term variability, episodes of high variability, uterine tone, glucose, lactate, nitrate, total cholesterol and HDL.The analysis will be based on intention to treat, according to the recommendations of the CONSORT (2010).

NCT ID: NCT01381380 Completed - Clinical trials for Myofascial Pain Syndromes

Manual Therapy Treatment for Myofascial Pain

Start date: November 2006
Phase: N/A
Study type: Interventional

This study is a pain intensity evaluation in patients with myofascial pain submitted kinesitherapy after trigger point injection.

NCT ID: NCT01381055 Completed - Clinical trials for Cutaneous Leishmaniasis

Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis

Start date: March 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether pentoxifylline associated to pentavalent antimony has a higher cure rate than pentavalent antimony alone in the treatment of cutaneous leishmaniasis.

NCT ID: NCT01380080 Completed - HIV Infection Clinical Trials

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

REMEMBER
Start date: October 2011
Phase: Phase 4
Study type: Interventional

People with HIV have a high chance of becoming infected with TB, especially when they live in areas where TB infection is common. It can be difficult to diagnose TB in people who need to start HIV treatment right away. Within about 6 months after starting HIV treatment, some of these people can become very sick with TB and can even die from it. This study was being done in people who were starting HIV treatment and who lived in areas where the TB infection rate is high. The purpose of this study was to test an experimental approach to TB treatment to see if it is better than the usual approach. The experimental approach was to start TB treatment at the same time as HIV treatment, even when TB infection had not been found. The usual approach was to start TB treatment only if TB infection was found. In this study, half of the people started TB treatment at the same time as they started their HIV treatment. The other half started TB treatment only if TB infection was found. The study also tested how safe and effective it was to start TB treatment at about the same time as HIV treatment even when TB infection had not been found. The study collected information about diet, whether (and when) people in the study became sicker or died, how well their HIV was controlled, how they were feeling, how they were taking their medications, whether it mattered where they lived or what kind of HIV and TB care was standard, how many people were diagnosed with TB while in the study, and how the cost of the two treatment options on a national level could be compared.

NCT ID: NCT01379534 Completed - Endometrial Cancer Clinical Trials

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Start date: November 2011
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.

NCT ID: NCT01379495 Completed - Burns Clinical Trials

Education Program for Burn Patients

Start date: July 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect of an educative program including telephone follow-up for burn patients regarding the impact of this intervention on the health status and return to work at six months after hospital discharge.

NCT ID: NCT01379326 Completed - Clinical trials for Ancylostoma Ceylanicum

Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

ConWorm
Start date: December 2011
Phase: Phase 4
Study type: Interventional

Objectives: The overall objective is to monitor efficacy of mebendazole (MBZ) against Soil-Transmitted Helminths (STH). The primary objective is: (1) to monitor the efficacy a single dose 500 mg of mebendazole (MBZ) against Soil-Transmitted Helminths (STH) infections by means of Faecal Egg Count Reduction (FECR) and Cure Rate (CR). The secondary objectives are: 1. to assess the occurrence of Necator americanus and Ancylostoma duodenal. 2. to assess the occurrence of β-tubulin mutations related to resistance before and after drug administration. 3. to evaluate the role of dogs and pigs as reservoir for zoonotic transmission.

NCT ID: NCT01379105 Completed - Clinical trials for Electromechanical Dissociation

Electromyographic Responses by Static Stretching and Neural Mobilization

Start date: August 2010
Phase: N/A
Study type: Interventional

The objective of this experimental study was to compare the electromyographic responses of sedentary youth with and without the administration of static stretching and neural mobilization. The sample was composed of sedentary students, divided, randomly, into neural mobilization practitioners (NMG; n=15; age=22±3 years), static stretching practitioners (SSG; n=15; age=23±4 years) and a control group (CG; n=15; age: 24±4 years). For this evaluation, an electromyograph (EMG; a four channel system) was used to monitor electrical activity in the femoral bicep muscles). In neural mobilization, hip flexion was conducted passively with the knee extended, and 30 plantar-to-dorsal flexion oscillations were completed per minute. For the static stretching, hip flexion with was completed passively with the knee extended and held for 6 seconds. The perception of effort was evaluated using the Perceived Force in Flexibility Scale. The statistical significance level was p<0.05. Descriptive statistics such as the average, standard deviation, median, standard error and absolute change within groups (post-test - pretest) were calculated. The sample normality was evaluated using the Shapiro-Wilk test. For the response variable analysis, the paired Student's t-test (paired) or Wilcoxon test (nonparametric) was used for intragroup analysis. For the intergroup analysis, the multivariate analysis of variance (ANOVA) test was used, followed by the Tukey Post-Hoc test. A p<0.05 significance level was adopted for the statistical evaluations. Microsoft Excel and the Statistical Package for Social Science (SPSS) version 14.0 were used for evaluation of the results.

NCT ID: NCT01378286 Completed - Malaria Clinical Trials

Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

Start date: January 2012
Phase: Phase 3
Study type: Interventional

Primary Objective: - To demonstrate the non-inferiority of corrected adequate clinical and parasitological response at Day 28 of Artesunate Amodiaquine (ASAQ) versus chloroquine Secondary Objectives: - To assess the non inferiority on the same way as the main criteria: - at Day 28 before corrected cure rate - at Day 14 and Day 42 before and after corrected cure rate - To compare the two groups of treatment in terms of: - Efficacy: - Proportion of aparasitaemic patients at 24, 48 an 72 hours - Proportion of afebrile patients at 24, 48 and 72 hours - Percentage of gametocyte carriers during follow-up - Evolution of the mean of gametocytes during the 42 days of follow-up - Evolution of haemoglobin value between Day 0 and Day 7, Day 0 and Day 28 - Clinical and biological tolerability: - Proportion of any adverse event - Biological safety: haematology (Red blood cells, Haemoglobin, White Blood Cells, neutrophils, platelets), biochemistry (creatinine, transaminases (alanine amino transferase/ALT), bilirubins) - ECG (electro encephalogram) (Day 0, Day 3,Day 28) only for patients 10 years old and above

NCT ID: NCT01377974 Completed - Leishmaniasis Clinical Trials

Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.